Search

everythinglearnresearchcommunity

for

Search:↓

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.

Targeted cancer therapies often cause serious skin problems that need careful management.

EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.

Cetuximab can cause excessive eyelash growth.

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

Cetuximab can cause eyelash growth, which is rare but manageable.

The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.

Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.

New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.

EGFR inhibitors can cause yellowish skin eruptions.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Erosive pustular dermatosis of the scalp is a rare condition that causes scarring hair loss, mainly in older women, and requires ongoing treatment.

Blocking EGFR in skin cells doesn't majorly increase inflammation markers.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Tofacitinib helped regrow hair in most patients with severe hair loss.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.